<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37114204</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity.</ArticleTitle><Pagination><StartPage>2344239</StartPage><MedlinePgn>2344239</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2344239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/2344239</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The role of T cells in the pathogenesis of systemic lupus erythematosus (SLE) has recently gained attention. Costimulatory molecules are membrane proteins strictly associated with T-cell receptor (TCR), acting by activating or inhibiting T cells and antigen-presenting cells (APC) through direct and reverse signaling, thus becoming responsible for the development of effector T cells or regulatory T cells. The primary objective of the present case-control study was to evaluate the cell membrane expression of CD137 on T cells and the serum concentration of CD137 (sCD137) in a SLE cohort.</AbstractText><AbstractText Label="MATERIALS" NlmCategory="UNASSIGNED">We enrolled SLE patients and sex/age-matched healthy subjects (HS). Disease activity was assessed by SLEDAI-2K. By application of flow cytometry, we evaluated the expression of CD137 on CD4+ and CD8+ lymphocytes. ELISA test was performed to evaluate serum levels of sCD137.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Twenty-one SLE patients (M/F 1/20; median age 48 years (IQR 17); median disease duration 144 months (IQR 204)) were evaluated. SLE patients showed %CD3+CD137+ cells significantly higher compared to HS (median 5.32 (IQR 6.11) versus 3.3 (IQR 1.8), <i>p</i> = 0.001). In SLE patients, %CD4+CD137+ cells positively correlated with SLEDAI-2K (<i>p</i> = 0.0082, <i>r</i>&#x2009;=&#x2009;0.58, CI (0.15-0.82); indeed, %CD4+CD137+ cells were significantly lower in SLE patients with a remission status compared to those not reaching this condition (median 1.07 (IQR 0.91) versus 1.58 (IQR 2.42), <i>p</i> = 0.013). Accordingly, sCD137 levels were significantly lower in remission status (31.30&#x2009;pg/mL (IQR 102.2 versus median 122.8&#x2009;pg/mL (IQR 536); <i>p</i> = 0.03) and correlated with %CD4+CD137+ cells (<i>p</i> = 0.012, <i>r</i>&#x2009;=&#x2009;0.60, CI (0.15-0.84)).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our results suggest a possible involvement of CD137-CD137L axis in SLE pathogenesis, as demonstrated by higher expression of CD137 on CD4+ cells in SLE compared with HS. Furthermore, the positive correlation between SLEDAI-2K and membrane CD137 expression on CD4+ cells, as well as soluble CD137, indicates a possible use as biomarkers for disease activity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Fulvia Ceccarelli et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceccarelli</LastName><ForeName>Fulvia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natalucci</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Filippo</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olivieri</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napoletano</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rughetti</LastName><ForeName>Aurelia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1863-8251</Identifier><AffiliationInfo><Affiliation>Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuti</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zizzari</LastName><ForeName>Ilaria Grazia</ForeName><Initials>IG</Initials><Identifier Source="ORCID">0000-0001-8263-7248</Identifier><AffiliationInfo><Affiliation>Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053261">Tumor Necrosis Factor Receptor Superfamily, Member 9</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="Y">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053261" MajorTopicYN="N">Tumor Necrosis Factor Receptor Superfamily, Member 9</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>2</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37114204</ArticleId><ArticleId IdType="pmc">PMC10129430</ArticleId><ArticleId IdType="doi">10.1155/2023/2344239</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsokos G. C. Systemic lupus erythematosus. New England Journal of Medicine . 2011;365(22):2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Z. X., Olsen N., Zheng S. G. The essential role of costimulatory molecules in systemic lupus erythematosus. Lupus . 2019;28(5):575&#x2013;582. doi: 10.1177/0961203319829818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319829818</ArticleId><ArticleId IdType="pubmed">30952199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada Y., Nagasawa K., Ho A., et al. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice. The Journal of Immunology . 1999;163(6):3153&#x2013;3159. doi: 10.4049/jimmunol.163.6.3153.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.163.6.3153</ArticleId><ArticleId IdType="pubmed">10477582</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacquemin C., Schmitt N., Contin-Bordes C., et al. OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response. Immunity . 2015;42(6):1159&#x2013;1170. doi: 10.1016/j.immuni.2015.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.05.012</ArticleId><ArticleId IdType="pmc">PMC4570857</ArticleId><ArticleId IdType="pubmed">26070486</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Huang W., Schiffer L. E., et al. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis and Rheumatism . 2003;48:495&#x2013;506. doi: 10.1002/art.10929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10929</ArticleId><ArticleId IdType="pubmed">12571860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak A., Schwarz H. The progress of investigating the CD137-CD137L axis as a potential target for systemic lupus erythematosus. Cells . 2019;8(9) doi: 10.3390/cells8091044.1044</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8091044</ArticleId><ArticleId IdType="pmc">PMC6770642</ArticleId><ArticleId IdType="pubmed">31500130</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz H., Tuckwell J., Lotz M. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene . 1993;134(2):295&#x2013;298. doi: 10.1016/0378-1119(93)90110-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-1119(93)90110-O</ArticleId><ArticleId IdType="pubmed">8262389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H. Y., Schwarz H. CD137/CD137 ligand signalling regulates the immune balance: a potential target for novel immunotherapy of autoimmune diseases. Journal of Autoimmunity . 2020;112 doi: 10.1016/j.jaut.2020.102499.102499</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102499</ArticleId><ArticleId IdType="pubmed">32505443</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel J., Langstein J., Hofst&#xe4;dter F., Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. European Journal of Immunology . 1998;28(1):290&#x2013;295. doi: 10.1002/(SICI)1521-4141(199801)28:01&lt;290::AID-IMMU290&gt;3.0.CO;2-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1521-4141(199801)28:01&lt;290::AID-IMMU290&gt;3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">9485208</ArticleId></ArticleIdList></Reference><Reference><Citation>Luu K., Shao Z., Schwarz H. The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention. Journal of Leukocyte Biology . 2020;107(5):731&#x2013;738. doi: 10.1002/JLB.2MR1119-224R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.2MR1119-224R</ArticleId><ArticleId IdType="pubmed">32052477</ArticleId></ArticleIdList></Reference><Reference><Citation>Thum E., Shao Z., Schwarz H. CD137, implications in immunity and potential for therapy. Frontiers in Bioscience (Landmark Edition) . 2009;14(11):4173&#x2013;4188. doi: 10.2741/3521.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3521</ArticleId><ArticleId IdType="pubmed">19273343</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis &amp; Rheumatology . 2019;71(9):1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli F., Saccucci M., Natalucci F., et al. Porphyromonas gingivalis amount in the tongue biofilm is associated with erosive arthritis in systemic lupus erythematosus. Lupus . 2022;31(8):921&#x2013;926. doi: 10.1177/09612033221098528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221098528</ArticleId><ArticleId IdType="pubmed">35477339</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen M., Iaccarino L., Gatto M., et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Annals of the Rheumatic Diseases . 2015;74(12):2117&#x2013;2122. doi: 10.1136/annrheumdis-2015-207347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207347</ArticleId><ArticleId IdType="pubmed">26223434</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinay D. S., Choi J. H., Kim J. D., Choi B. K., Kwon B. S. Role of endogenous 4-1BB in the development of systemic lupus erythematosus. Immunology . 2007;122(3):394&#x2013;400. doi: 10.1111/j.1365-2567.2007.02653.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02653.x</ArticleId><ArticleId IdType="pmc">PMC2266025</ArticleId><ArticleId IdType="pubmed">17608689</ArticleId></ArticleIdList></Reference><Reference><Citation>Foell J., Strahotin S., O&#x2019;Neil S. P., et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB &#xd7; NZW F1 mice. The Journal of Clinical Investigation . 2003;111(10):1505&#x2013;1518. doi: 10.1172/JCI200317662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200317662</ArticleId><ArticleId IdType="pmc">PMC155050</ArticleId><ArticleId IdType="pubmed">12750400</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P.-M., Tsokos G. C. T cell abnormalities in the pathogenesis of systemic lupus erythematosus: an update. Current Rheumatology Reports . 2021;23(2) doi: 10.1007/s11926-020-00978-5.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00978-5</ArticleId><ArticleId IdType="pmc">PMC8601587</ArticleId><ArticleId IdType="pubmed">33512577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon B. Is CD137 ligand (CD137L) signaling a fine tuner of immune responses? Immune Network . 2015;15(3):121&#x2013;124. doi: 10.4110/in.2015.15.3.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2015.15.3.121</ArticleId><ArticleId IdType="pmc">PMC4486774</ArticleId><ArticleId IdType="pubmed">26140043</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H. W., Choi S. W., Choi J. I. L., Kwon B. S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Experimental &amp; Molecular Medicine . 2004;36(1):13&#x2013;22. doi: 10.1038/emm.2004.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2004.2</ArticleId><ArticleId IdType="pubmed">15031666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>